Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-stage multicenter phase II trial of concurrent induction with EOC and panitumumab in gastric cancer
2009-011337-27Phase 2Terminated
- Sponsor
- AGMT
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in gastric cancer (GC), sponsored by AGMT. Primary endpoints: Neoadjuvant activity (T0/T1 proportion) and Tolerability (grade 4 diarrhea). Started Feb 2010; status: terminated.
02
Drugs
panitumumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on 2009-011337-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011337-27.